Insinga RP - Search Results

1

Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. White RR, et al. Among authors: insinga rp. Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000. Pharmacoeconomics. 2009. PMID: 19757871

2

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Insinga RP, Itzler RF, Pellissier JM. Insinga RP, et al. Pharmacoeconomics. 2007;25(2):155-69. doi: 10.2165/00019053-200725020-00007. Pharmacoeconomics. 2007. PMID: 17249857

3

The incidence of herpes zoster in a United States administrative database.

Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. Insinga RP, et al. J Gen Intern Med. 2005 Aug;20(8):748-53. doi: 10.1111/j.1525-1497.2005.0150.x. J Gen Intern Med. 2005. PMID: 16050886 Free PMC article.

4

Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.

Insinga RP, Ye X, Singhal PK, Carides GW. Insinga RP, et al. Gynecol Oncol. 2008 Nov;111(2):188-96. doi: 10.1016/j.ygyno.2008.07.032. Epub 2008 Aug 30. Gynecol Oncol. 2008. PMID: 18757080

5

Assessing incidence and economic burden of genital warts with data from a US commercially insured population.

Hoy T, Singhal PK, Willey VJ, Insinga RP. Hoy T, et al. Among authors: insinga rp. Curr Med Res Opin. 2009 Oct;25(10):2343-51. doi: 10.1185/03007990903136378. Curr Med Res Opin. 2009. PMID: 19650749

6

Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population.

Henk HJ, Insinga RP, Singhal PK, Darkow T. Henk HJ, et al. Among authors: insinga rp. J Low Genit Tract Dis. 2010 Jan;14(1):29-36. doi: 10.1097/LGT.0b013e3181ac05e9. J Low Genit Tract Dis. 2010. PMID: 20040833

7

Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.

Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, Hsu DC, Lee MYK, Huang M, Pellissier J, Rai A, Achra M, Tan SC. Loong HH, et al. Among authors: insinga rp. Pharmacoecon Open. 2020 Jun;4(2):235-247. doi: 10.1007/s41669-019-00178-7. Pharmacoecon Open. 2020. PMID: 31531842 Free PMC article.

8

Five-year routine cervical cancer screening rates and intervals in a US health plan.

Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA. Schabert VF, et al. Among authors: insinga rp. Curr Med Res Opin. 2008 Sep;24(9):2429-35. doi: 10.1185/03007990802281671. Epub 2008 Jul 24. Curr Med Res Opin. 2008. PMID: 18662493

9

Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.

Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER. Insinga RP, et al. Value Health. 2008 Dec;11(7):1022-32. doi: 10.1111/j.1524-4733.2008.00342.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489503 Free article. Clinical Trial.

10

Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Insinga RP, Dasbach EJ, Elbasha EH. Insinga RP, et al. Pharmacoeconomics. 2005;23(11):1107-22. doi: 10.2165/00019053-200523110-00004. Pharmacoeconomics. 2005. PMID: 16277547 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters